Accord BioPharma Introduces FILKRI™: A New G-CSF Biosimilar for Cancer Care#United_States#Raleigh#oncology#Accord_BioPharma#FILKRI
Accord BioPharma Introduces FILKRI™: A New G-CSF Biosimilar for Cancer Care
Accord BioPharma has launched FILKRI™, a new biosimilar to Neupogen®, enhancing treatment options for patients undergoing chemotherapy.
third-news.com
October 12, 2026 at 12:17 PM
Accord BioPharma Introduces FILKRI™: A New G-CSF Biosimilar for Cancer Care#United_States#Raleigh#oncology#Accord_BioPharma#FILKRI
FDA Approves Accord’s FILKRI (filgrastim-laha), a Biosimilar to NEUPOGEN
FDA Approves Accord’s FILKRI (filgrastim-laha), a Biosimilar to NEUPOGEN
On February 17, 2026, the U.S. Food and Drug Administration (FDA) approved FILKRI (filgrastim-laha), a biosimilar to Amgen’s NEUPOGEN...
www.jdsupra.com
February 23, 2026 at 5:57 PM
FDA Approves Accord’s FILKRI (filgrastim-laha), a Biosimilar to NEUPOGEN
FDA Approves Accord’s FILKRI (filgrastim-laha), a Biosimilar to NEUPOGEN
FDA Approves Accord’s FILKRI (filgrastim-laha), a Biosimilar to NEUPOGEN
On February 17, 2026, the U.S. Food and Drug Administration (FDA) approved FILKRI (filgrastim-laha), a biosimilar to Amgen’s NEUPOGEN...
www.jdsupra.com
February 23, 2026 at 5:57 PM
FDA Approves Accord’s FILKRI (filgrastim-laha), a Biosimilar to NEUPOGEN
FDA Approves Accord’s Neupogen® Biosimilar Filkri™ (filgrastim-laha)
FDA Approves Accord’s Neupogen® Biosimilar Filkri™ (filgrastim-laha)
On February 17, 2026, Accord BioPharma announced the FDA approval of Filkri™ (filgrastim-laha), a biosimilar of Amgen’s Neupogen® (filgrastim). ...
www.jdsupra.com
February 20, 2026 at 5:14 PM
FDA Approves Accord’s Neupogen® Biosimilar Filkri™ (filgrastim-laha)
FDA Approves Accord’s FILKRI (filgrastim-laha), a Biosimilar to NEUPOGEN
FDA Approves Accord’s FILKRI (filgrastim-laha), a Biosimilar to NEUPOGEN
On February 17, 2026, the U.S. Food and Drug Administration (FDA) approved FILKRI (filgrastim-laha), a biosimilar to Amgen’s NEUPOGEN...
www.jdsupra.com
February 23, 2026 at 5:57 PM
FDA Approves Accord’s FILKRI (filgrastim-laha), a Biosimilar to NEUPOGEN
